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Genetic Defects in Human Pericentrin Are Associated
With Severe Insulin Resistance and Diabetes
Isabel Huang-Doran,1 Louise S. Bicknell,2 Francis M. Finucane,3 Nuno Rocha,1 Keith M. Porter,1
Y.C. Loraine Tung,1 Ferenc Szekeres,4 Anna Krook,4 John J. Nolan,3 Mark O’Driscoll,5
Michael Bober,6 Stephen O’Rahilly,1 Andrew P. Jackson,2 and Robert K. Semple,1 for the Majewski
Osteodysplastic Primordial Dwarﬁsm Study Group*
OBJECTIVE—Genetic defects in human pericentrin (PCNT),
encoding the centrosomal protein pericentrin, cause a form of
osteodysplastic primordial dwarﬁsm that is sometimes reported
to be associated with diabetes. We thus set out to determine the
prevalence of diabetes and insulin resistance among patients with
PCNT defects and examined the effects of pericentrin depletion
on insulin action using 3T3-L1 adipocytes as a model system.
RESEARCH DESIGN AND METHODS—A cross-sectional
metabolic assessment of 21 patients with PCNT mutations was
undertaken. Pericentrin expression in human tissues was proﬁled
using quantitative real-time PCR. The effect of pericentrin knock-
down on insulin action and adipogenesis in 3T3-L1 adipocytes
was determined using Oil red O staining, gene-expression analy-
sis, immunoblotting, and glucose uptake assays. Pericentrin ex-
pression and localization also was determined in skeletal muscle.
RESULTS—Of 21 patients with genetic defects in PCNT, 18 had
insulin resistance, which was severe in the majority of subjects.
Ten subjects had conﬁrmed diabetes (mean age of onset 15 years
[range 5–28]), and 13 had metabolic dyslipidemia. All patients
without insulin resistance were younger than 4 years old. Knock-
down of pericentrin in adipocytes had no effect on proximal
insulin signaling but produced a twofold impairment in insulin-
stimulated glucose uptake, approximately commensurate with an
associated defect in cell proliferation and adipogenesis. Pericen-
trin was highly expressed in human skeletal muscle, where it
showed a perinuclear distribution.
CONCLUSIONS—Severe insulin resistance and premature di-
abetes are common features of PCNT deﬁciency but are not con-
genital. Partial failure of adipocyte differentiation may contribute
to this, but pericentrin deﬁciency does not impair proximal in-
sulin action in adipocytes. Diabetes 60:925–935, 2011
Insulin resistance is at pandemic levels and is as-sociated with major mortality and morbidity predom-inantly attributed to atherosclerosis, microvascularcomplications of diabetes, hepatic steatosis, and
polycystic ovary syndrome (1). Pandemic insulin resistance
is likely to be accounted for by an oligogenic diathesis
interacting with environmental factors, by far the most im-
portant of which is obesity (2,3). However, studies to date
have identiﬁed only a handful of common genetic variants
plausibly associated with insulin resistance risk, collec-
tively accounting for only a small proportion of the in-
sulin resistance in the general population (4–6).
We have adopted a complementary strategy to pop-
ulation-wide genetic approaches, ﬁrst by identifying single-
gene defects in rare patients with unusually severe insulin
resistance and then by comparing and contrasting their
perturbed physiology with that of prevalent forms of in-
sulin resistance. In a large cohort of patients with extreme
insulin resistance, we identiﬁed two patients with osteo-
dysplastic primordial dwarﬁsm of Majewski type 2 (MOPDII;
MIM 210720), recently shown to be caused by mutations in
the PCNT gene (7,8). PCNT encodes pericentrin, a 360-kDa
coiled-coil protein that localizes to the pericentriolar
matrix throughout the cell cycle (9–12). This ﬁnding, to-
gether with scattered reports of early-onset diabetes and
acanthosis nigricans in patients with clinical features of
MOPDII, led us to study the prevalence and natural history
of insulin resistance in patients with PCNT loss-of-function
mutations (7,8,13). In addition, we used an in vitro ap-
proach to explore the role of pericentrin in insulin action.
Using the 3T3-L1 adipocyte cell line as a model system,
the effects of pericentrin deﬁciency on insulin respon-
siveness and adipocyte differentiation, both of which
make key contributions to metabolic homeostasis in vivo,
were assessed.
RESEARCH DESIGN AND METHODS
Patients with insulin resistance and MOPDII were identiﬁed as part of a long-
standing program of research into severe insulin resistance. All physiological
and genetic studies were approved by the National Health Service Research
Ethics Committee of the U.K. Each participant provided written informed
consent, and all studies were conducted in accordance with the principles of
the Declaration of Helsinki. Additional patients with MOPDII and proven PCNT
mutations underwent a basic metabolic evaluation as part of their routine
clinical care.
Genetic studies. The sequence analysis of the PCNT gene has been described
previously (7,8). Single nucleotide polymorphism genotyping and copy-number
analysis of patient 2 and her father was undertaken using Affymetrix 6.0 chips,
with data analyzed using the Affymetrix Genotyping Console (Santa Clara, CA).
Biochemical assays. Venous blood was drawn in the fasting state, and plasma
was immediately extracted and stored at 220°C. Insulin, leptin, and
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adiponectin were assayed using two-step time-resolved AutoDELFIA immu-
noassays, as previously described (14–16). All other analytes were determined
in accredited clinical diagnostic laboratories of referring hospitals. For oral
glucose tolerance testing, 1.75 g glucose/kg body wt was given after a 10-h fast,
and blood samples were taken at the times indicated for determination of
plasma glucose and insulin.
Body composition and abdominal fat measurement. Body composition
was measured by Lunar Prodigy dual-energy X-ray absorptiometry (GE Lunar),
and proton magnetic resonance spectroscopy (MRS) was undertaken using
a Siemens 3T Tim Trio MR scanner and protocols described in detail previously
(15).
Cell culture. All reagents were obtained from Sigma-Aldrich (St. Louis, MO),
unless otherwise indicated. Cells were cultured in 100 units/L penicillin, 100 mg/
mL streptomycin, and 2 mmol/L L-glutamine. Generation and culture of
Epstein-Barr virus–transformed lymphoblastoid cell lines and dermal ﬁbro-
blasts are described in the Supplementary Methods. Human embryonic kidney
293–BOSC packaging cells (Dr. J. Rochford, University of Cambridge) were
maintained in DMEM with FBS (DMEM-FBS). Murine 3T3-L1 preadipocytes
(American Tissue Culture Collection, Manassas, VA) were maintained below
70% conﬂuence in DMEM with neonatal calf serum. To induce adipocyte dif-
ferentiation, 2-day postconﬂuent preadipocytes were transferred to DMEM-
FBS, supplemented with 500 mmol/L 3-isobutyl-1-methylxanthine (3 days), 1
mmol/L dexamethasone (3 days), 10 mmol/L insulin (6 days; Novo Nordisk;
Bagsværd, Denmark), and 100 nmol/L rosiglitazone (6 days). Experiments
were performed 10 days after inducing differentiation. Differentiation was
assessed by staining formalin-ﬁxed adipocytes with 1.5 mmol/L Oil-Red-O in
isopropanol (17). For proliferation studies, cell numbers were quantiﬁed using
the CyQuant Cell Proliferation assay (Invitrogen, Carlsbad, CA).
Short-hairpin RNA–mediated pericentrin knockdown. Short-hairpin RNA
(shRNA) constructs targeting murine Pcnt (NM_008787) (shPcnt1: 59-AAT-
GAGGTTGTCCACAGGAGA-39; shPcnt2: 59-CGGTCTTGTGGAACCAGAA-39)
and ﬁreﬂy luciferase as a control (shLuc) were cloned into the RNA-Ready
pSIREN-RetroQ Vector (Clontech, Palo Alto, CA). Infectious retroviruses were
generated in BOSC-293 cells before infection of 3T3-L1 preadipocytes
(Supplementary Methods) (17).
Gene-expression analysis. A commercial human-tissue RNA panel was
obtained from AMS Biotechnology (Abingdon, U.K.); the murine-tissue RNA
panel was a gift from Dr. Giles Yeo (University of Cambridge). Total RNA was
extracted from cells using the RNEasy kit (Qiagen). Reverse transcription was
performed using Moloney murine leukemia virus reverse transcriptase, random
hexamers, and deoxynucleotide triphosphates, as per the manufacturer’s
guidelines (Promega, Madison, WI). Real-time quantitative PCR used an ABI
7900 detection system (Applied Biosystems, Foster City, CA), a Taqman PCR
Mastermix (Applied Biosystems), gene-speciﬁc forward and reverse primers,
and 59-[FAM], 39[TAMRA]-labeled ﬂuorogenic probes. Sequences or catalog
numbers for all primers and probes used are listed in the Supplementary
Material.
Western blotting. Cell lysis was performed as described previously (18).
Protein concentrations were determined using the Bio-Rad Dc Protein Assay
(Bio-Rad, Hercules, CA). Proteins were denatured at 95°C then resolved by
SDS-PAGE and transferred to polyvinylidene ﬂuoride membranes using the
iBlot system (Invitrogen). Membranes were blocked in 5% milk before im-
munoblotting. Sources of all primary antibodies are listed in the Supplemen-
tary Material. Horseradish peroxide–conjugated secondary antibodies were
obtained from Thermo Pearce and visualized using an enhanced chemo-
luminescence system (GE Healthcare).
Deoxyglucose uptake assay. Serum-starved adipocytes were exposed to 100
nmol/L insulin or PBS in glucose-free HEPES buffer for 30 min followed by
incubation in 1 mCi/mL [3H]deoxyglucose for 5 min. Cells were lysed in 0.5
mol/L potassium hydroxide, neutralized in 0.5 mol/L hydrochloric acid, and
intracellular 3H was measured using Hionic-Fluor scintillant (Perkin Elmer)
in a Tri-Carb 2100-TR Liquid Scintillation Analyzer (Packard). Radioactivity
was normalized to protein concentration, which was determined using the
Coomassie Plus Protein Assay (Thermo-Fisher Scientiﬁc).
Immunocytochemistry and immunohistochemistry. Cells grown on glass
cover slips were ﬁxed in ice-cold methanol or 3–4% neutral-buffered formal-
dehyde, followed by permeabilization in 0.5% saponin. Vastus lateralis biopsies
were obtained from healthy volunteers (19), sectioned at 223°C, dried, and
then ﬁxed for 20 min in acetone at room temperature. All samples were
blocked in 1% BSA before antibody treatment. Sources of all primary and
secondary antibodies are listed in the Supplementary Material. Cells were
mounted in ProLong Gold Antifade with DAPI (Invitrogen) and viewed using
a Zeiss LSM510 MetaLaser Scanning Microscope (Carl Zeiss, Jena, Germany).
Statistical analysis. Differences in gene expression or glucose uptake be-
tween multiple groups or at different time points were evaluated by ANOVA
with post hoc Bonferroni tests. Differences in cell proliferation rates were
assessed by ﬁtting linear regression lines then testing for gradient equality. All
analyses were performed in GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA).
RESULTS
Early-onset, progressive insulin resistance in patients
with PCNT defects. As part of a long-running program of
investigation of severe insulin resistance, two patients were
identiﬁed with severe insulin resistance as well as clinical
features of MOPDII, as summarized in the Supplementary
Results. Patient 1 (patient 23 in Rauch et al. [8]), a 29-year-
old man, had compound heterozygous nonsense mutations
in PCNT, with a 60% reduction in PCNT mRNA levels, loss
of punctate juxtanuclear pericentrin immunostaining, and
disorganization of the microtubule network in dermal ﬁ-
broblasts. Pericentrin protein expression was nearly absent
in Epstein-Barr virus–transformed lymphoblastoid cells
(Supplementary Fig. 2). Patient 2 (patient 20 in Rauch et al.
[8]), a 10-year-old girl, had a homozygous nonsense muta-
tion in PCNT attributed to uniparental inheritance of the
terminal part of chromosome 21 harboring a heterozygous
mutation in her mother (Supplementary Fig. 4).
Patient 1. During evaluation of retarded growth at 3 years
old, 0.016 units insulin/kg body wt produced an adequate
hypoglycemia and growth-hormone response, suggesting
no severe insulin resistance. A 6-month trial of growth
hormone followed but was stopped because of inefﬁcacy. At
age 7 years, hypothyroidism was diagnosed and L-thyroxine
replacement was started. At age 12 years, a centripetal
distribution of adiposity associated with acanthosis ni-
gricans was ﬁrst noted. At age 15 years, testosterone re-
placement was commenced because of arrested puberty.
From age 21 years, severe acanthosis nigricans prompted
serial metabolic evaluations that showed consistent ex-
treme insulin resistance, severe mixed dyslipidemia, and,
ultimately, diabetes at age 23 years (Table 1). Over the
subsequent 4 years, good metabolic control was achieved
on metformin and fenoﬁbrate before the addition of rosi-
glitazone at age 28 years, when HbA1c was 8.5%.
On examination at the age of 29 years, patient 1 was of
extremely short stature, with characteristic dysmorphic
features of MOPDII and a centripetal pattern of adiposity;
however, although he had a relative paucity of adipose
tissue on his legs, there was no frank lipodystrophy. There
was ﬂorid acanthosis nigricans in the axillae, periumbilical
region, antecubital fossae, groin, and neck. He was nor-
mally androgenized with androgenic alopecia, and his
blood pressure was 100/55 mmHg. Oral glucose tolerance
testing conﬁrmed severely insulin-resistant diabetes and
dyslipidemia (Tables 1 and 2). Adiponectin was severely
suppressed, whereas leptin was slightly above the age- and
BMI-adjusted normal range. Body composition analysis
showed pronounced centripetal fat distribution, and MRS
revealed hepatic steatosis (Table 2).
Clinical assessment and genotyping of the extended
family of patient 1 provided no evidence that hetero-
zygotes for either of the truncating mutations had re-
duced height or insulin sensitivity compared with family
members wild-type for PCNT (Supplementary Fig. 1,
Supplementary Table 3).
Patient 2. At age 4 years, patient 2 was evaluated for
severe growth retardation, which led to the commence-
ment of growth-hormone therapy at age 4.2 years. Despite
dose titration to 0.5 mg/day, growth velocity remained
poor, and IGF-1 at age 6.4 years remained low (18 nmol/L
[normal range 24–46]). At age 8.9 years, centripetal weight
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gain and severe acanthosis nigricans were noted. Labora-
tory studies showed a normal HbA1c (6%) but elevated
IGF-1 (75 nmol/L) and marked dyslipidemia (cholesterol
243 mg/dL, triglycerides 286 mg/dL) (Table 3). As a result,
growth-hormone therapy was stopped with no discernible
decline in growth velocity.
Two months later (at age 9.1 years), fasting glucose was
normal but acanthosis nigricans and dyslipidemia had
worsened (cholesterol 309 mg/dL, triglycerides 912 mg/dL)
(Table 3). There was mildly deranged liver function (67
units/L alanine aminotransferase [ALT]), and ultrasonogra-
phy showed hyperechoic echotexture of the liver, consistent
with steatosis. Four months after cessation of growth-
hormone therapy (at age 9.2 years), lipids remained elevated
but had improved (cholesterol 212 mg/dL, triglycerides
221 mg/dL). Fasting hyperinsulinemia was noted, but there
was no impaired glucose tolerance (Table 3). IGF-1 levels
had normalized (34 nmol/L). However, on investigation at
TABLE 1
Serial oral glucose tolerance testing in patient 1
Age (years)
21 22.8 29
Treatment
NIL NIL
500 mg metformin, 2 mg rosiglitazone,
200 mg fenoﬁbrate
Time (min)
Glucose
(mg/dL)
Insulin
(pmol/L)
Glucose
(mg/dL)
Insulin
(pmol/L)
Glucose
(mg/dL)
Insulin
(pmol/L)
Free fatty acids
(mmol/L)
0 72 1,990 191 2,640 114 132 327
30 189 13,900 306 4,010 220 559
60 229 18,900 384 4,700 279 1,260 251
90 202 19,900 411 6,770 308 1,550
120 207 23,000 436 11,100 295 1,900 143
Fasting reference range 68–100 ,60 68–100 ,60 68–100 ,60
TABLE 2
Metabolic evaluation of patients 1 and 2
Patient 1 Patient 2 Fasting reference range
Age at evaluation (years) 29.0 10.7
Sex Male Female
Therapy 500 mg metformin,
2 mg rosiglitazone,
200 mg fenoﬁbrate
500 mg metformin
Height (m) 1.11 1.09
Weight (kg) 28.7 24.3
BMI (kg/m2) 23.3 20.5 18.5–25
Waist-to-hip ratio 0.86 1.00
HbA1c (%) 9.1 5.6 8.0–13.2
Total cholesterol (mg/dL) 251.0 196.9 ,200
Triglycerides (mg/dL) 486.7 300.9 ,177
HDL cholesterol (mg/dL) 11.2 52.1 .39
LDL cholesterol (mg/dL) ND 86.9 ,130
Adiponectin (mg/L) 1.1 1.1 *
Leptin (mg/L) 9.7 28.1 *
SHBG (nmol/L) 13 9 †
IGFBP1 (ng/mL) 29.5 4.1 10–120
gGT (units/L) 61 233 0–33
ALT (units/L) 27 98 0–50
Dual-energy X-ray absorptiometry data
Percentage fat (SD score) 21.8 (20.72) 33.6 (0.24)
Percentage fat (arms) 18.5 32.5
Percentage fat (legs) 14.9 28.4
Percentage fat (trunk) 26.7 38.7
Percentage android 34.4 46.8
MRS data
Percentage fat (liver) 7.9 ND
SD scores for percentage fat were derived from published data from age- and sex-matched control populations (29). *Reference ranges for
leptin and adiponectin are dependent on sex and body weight. The relevant sex- and BMI-adjusted 95% population ranges for leptin and
adiponectin are 0.4–8.3 mg/L and 2.6–12.6 mg/L, respectively, for patient 1 and 2.4–24.4 mg/L and 4.4–17.7 mg/L, respectively, for patient 2.
†Reference ranges for SHBG are dependent on sex. Relevant ranges are 15–48 nmol/L for patient 1 and 26–110 nmol/L for patient 2. gGT,
g glutamyltransferase; FHS, follicle-stimulating hormone; LH, luteinizing hormone; ND, not done; TSH, thyroid-stimulating hormone.
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age 10.2 years, 15 months after cessation of growth hor-
mone, serum liver indices and lipid proﬁle remained de-
ranged, and oral glucose tolerance testing showed severe
hyperinsulinemia and diabetes (Table 3).
Metformin was commenced at age 10.2 years, and
a more detailed endocrine assessment was undertaken 6
months later, almost 2 years after cessation of growth-
hormone therapy. Physical examination revealed signs of
early puberty (Tanner stage A1, P2, B2), pronounced
acanthosis nigricans in the nuchal regions and axillae,
centripetal fat distribution, and 2–3 cm palpable hepato-
megaly but no lipodystrophy. Despite a normal HbA1c, oral
glucose tolerance testing again showed severe hyper-
insulinemia, with persisting fasting dyslipidemia, relatively
high leptin, and low adiponectin (Tables 2 and 3). ALT
remained elevated, consistent with hepatic steatosis. Body
composition analysis showed satisfactory bone-mineral
density and centripetal fat distribution (Table 2).
Cross-sectional metabolic assessment of a cohort of
patients with PCNT defects. In view of the severity of
the insulin resistance in the two index patients, allied to
scattered reports of early-onset diabetes in MOPDII
(7,8,13), metabolic assessment was undertaken of all other
available patients with MOPDII and proven genetic defects
in PCNT (Table 4). Of 21 patients reviewed, all of whom
were under age 30 years, 18 exhibited either fasting
hyperinsulinemia or clinical evidence of insulin resistance,
including acanthosis nigricans (15 patients). A total of 10
had early-onset diabetes (mean age at diagnosis 15 years
[range 5–28]). The three patients who had no evidence of
insulin resistance were all under 4 years old, indicating
that severe insulin resistance in MOPDII is not congenital
but appears during childhood or adolescence. Particularly
notable was the observation of an insulin-sensitive boy
(patient 4), aged 3 years, with MOPDII who had a 13-year-
old sister (patient 12) with the same genotype, MOPDII,
and severely insulin-resistant diabetes. Dyslipidemia also
was a common feature, with 13 patients for whom data
were available showing hypertriglyceridemia and/or low
HDL cholesterol. In two patients, clinical and/or bio-
chemical evidence of insulin resistance was ﬁrst noted
during or shortly after growth-hormone therapy. Additional
metabolic histories are provided in the Supplementary
Materials.
shRNA-mediated knockdown of pericentrin in 3T3-L1
murine preadipocytes. The extreme metabolic syndrome
observed in patients with PCNT defects closely resembles
the deranged metabolism seen in primary forms of lip-
odystrophy (20) but is unlike the severe insulin resistance
with normal lipid proﬁle of patients with insulin receptor
defects (15). This led us to hypothesize that loss of peri-
centrin function may compromise the function of adipose
tissue in metabolic homeostasis, either as a result of de-
fective adipogenesis, leading to a state of relative “fat
failure,” or through a cell-autonomous defect in adipocyte
insulin action, associated with defects in proximal insulin
signaling or abnormal GLUT4 trafﬁcking. To test these
hypotheses, 3T3-L1 preadipocytes were generated, stably
expressing shRNA against Pcnt (shPcnt1 and shPcnt2) or
ﬁreﬂy luciferase as a control (shLuc). shRNA expression
reduced Pcnt mRNA levels by .70% (Fig. 1A) and nearly
abolished protein expression (Fig. 1B), whereas immu-
nostaining revealed nearly absent centrosomal pericentrin
(Fig. 1C). Expression of pericentrin mRNA in wild-type,
shPcnt1/2, and shLuc cells was assessed throughout the
course of adipocyte differentiation. Both wild-type and
luciferase knockdown cells showed a consistent doubling
of pericentrin expression at day 1, returning to baseline by
day 4. Pericentrin expression in knockdown cells was
markedly lower than control cells throughout differentia-
tion (Fig. 1D and E).
Effect of pericentrin knockdown on 3T3-L1 differ-
entiation. Hormonal induction of differentiation in all
cell lines resulted in characteristic morphological changes
within 24 h, cell proliferation after 36 h, and lipid-droplet
appearance after 3 days. By day 8, most control cells
contained multiple small lipid droplets. In contrast, dif-
ferentiation was patchy in knockdown cell lines, with
regions of lipid accumulation interspersed with areas
devoid of lipid droplets. Oil-Red-O staining of mature adi-
pocytes conﬁrmed that pericentrin knockdown was associ-
ated with a marked impairment in triglyceride accumulation
TABLE 3
Serial metabolic assessment of Patient 2
Age (years)
8.9 9.1 9.2 10.2 10.7
Treatment
Growth
hormone
(1 month)
Off growth
hormone
(2 months)
Off growth
hormone
(4 months)
Off growth
hormone
(15 months)
500 mg metformin;
off growth hormone
(21 months)
Triglycerides (mg/dL)
normal range ,177 655 912 221 248 451
Cholesterol (mg/dL)
normal range ,200 243 309 212 205 131
Time (min) ND ND
Glucose
(mg/dL)
Insulin
(pmol/L)
Glucose
(mg/dL)
Insulin
(pmol/L)
Glucose
(mg/dL)
Insulin
(pmol/L)
FFA
(mmol/L)
0 ND ND 81 306 85 133 76 183 846
30 ND ND 153 .1230 ND ND 204 3850 640
60 ND ND 153 .1230 ND ND 218 3750 235
90 ND ND 124 .1230 ND ND 225 4430 206
120 ND ND 141 .1230 308 .1000 178 4910 171
Fasting reference range 68–100 ,60 68–100 ,60 68–100 ,60
ND, not done or data unavailable.
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(Fig. 2A), accompanied by a concomitant mild to moderate
(20–40%) defect in the expression of mature adipocyte
genes, including Pparg2, Glut4, Fabp4, Insr, and Acrp30
(Fig. 2B). However, the timing of adipocyte gene induction
was normal, with early upregulation of Insr followed by
Fabp4 and Glut4 (Supplementary Fig. 5).
Although controversial, evidence has been advanced
that two rounds of mitosis (so-called “clonal expansion”)
FIG. 1. Stable knockdown of Pcnt in murine 3T3-L1 preadipocytes. A: Pcnt mRNA expression in shPcnt-infected preadipocytes (□, shPcnt1;▨,shPcnt2) and luciferase knockdown control preadipocytes (■, shLuc) determined by quantitative real-time PCR. **P < 0.01 vs. shLuc (n = 4). B:
Pericentrin expression in shPcnt and shLuc preadipocytes assessed by Western blotting. Calnexin expression was evaluated as a loading control.
Representative example of three experiments. C: Expression and localization of pericentrin (green), g-tubulin (red), a-tubulin (green, far right
panels only), and nuclear material (blue, stained with DAPI) in shPcnt and shLuc preadipocytes, assessed by immunocytochemistry and confocal
microscopy. Arrowheads indicate juxtanuclear pericentrin. Scale bars: 20 mm (far left and far right panels) and 5 mm (central panels). D: Pcnt
mRNA expression during differentiation of wild-type 3T3-L1 cells, determined by quantitative real-time PCR. **P < 0.01; ***P < 0.005 vs. day
0 (n = 4). E: PcntmRNA expression during differentiation of shLuc (■) and shPcnt (□ and▨) preadipocytes. #P< 0.005 vs. shLuc (n = 4). All dataare means 6 SE. AU, arbitrary units. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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are a necessary ﬁrst step in adipogenesis (21). Given the
proposed role of pericentrin in mitotic spindle organization,
we hypothesized that the differentiation defect resulted
from a reduced efﬁciency of mitosis associated with the
absence of pericentrin. As well as displaying a higher
frequency of morphological abnormality (not shown),
quantiﬁcation of cell proliferation revealed a signiﬁcant
reduction in preconﬂuent proliferation of pericentrin
FIG. 2. Pcnt knockdown in 3T3-L1 preadipocytes is associated with impaired adipocyte differentiation. A: Oil red O staining of triglycerides at day
10 of differentiation in Pcnt knockdown and control adipocytes. Representative of n = 9. B: Relative adipocyte gene expression in Pcnt knockdown
(□ and▨) and control (■) cells at day 10 after differentiation. *P< 0.05; **P< 0.01; #P< 0.005 vs. shLuc (n = 9). C: Proliferation of shPcnt (bluecircles) and control (red squares) preadipocytes during the preconﬂuent growth phase (n = 4). Representative experiments are shown. Data are
means6 SE of four wells. D: Relative preconﬂuent rate of proliferation in shPcnt (▨) and control (■) preadipocytes (n = 3). E: Cell proliferationduring the preconﬂuent phase, conﬂuency, and after hormonal induction of differentiation. Representative experiments are shown. Data are
means 6 SE of four wells. F: Relative rate of cell proliferation after induction of differentiation (n = 3). AU, arbitrary units. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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knockdown preadipocytes compared with control cells
(Fig. 2C and D). Cell number at conﬂuence was consis-
tently slightly lower in the knockdown cells. Both cell lines
subsequently showed comparable, robust expansion in cell
number after induction of differentiation, with a lower ﬁ-
nal cell number in knockdown cells (Fig. 2E and F).
Cell-autonomous insulin action after pericentin
knockdown. We next tested the hypothesis that severe
insulin resistance results from a cell-autonomous defect in
insulin signaling, associated with either impaired proximal
insulin signaling or GLUT4 translocation. Knockdown of
pericentrin had no effect on insulin-stimulated autophos-
phorylation of its receptor or phosphorylation of two key
downstream kinases, protein kinase B (AKT) and extra-
cellular signal–regulated kinase 1/2 (ERK) (Fig. 3A). To
assess the integrity of the whole signaling pathway from
insulin receptor activation to GLUT4 vesicle fusion with
the plasma membrane, we next measured insulin-stimu-
lated glucose uptake by differentiated 3T3-L1 adipocytes.
Both knockdown and control cells showed a robust, four-
fold increase in deoxyglucose uptake, implying that trans-
location of GLUT4 to the plasma membrane in response to
insulin stimulation is intact (Fig. 3B). However, both
basal and insulin-stimulated glucose uptake were ~50%
lower in knockdown compared with control cells, which
was approximately commensurate with the degree of im-
pairment in differentiation and argues against any addi-
tional cell-autonomous defect in insulin signal transduction
in these cells. Consistently, immunostaining of endoge-
nous GLUT4 in mature, unstimulated adipocytes revealed
abundant perinuclear GLUT4 with no apparent difference
between knockdown and control cell lines (Fig. 3C).
Human pericentrin is more abundant in skeletal
muscle than any other tissue. To investigate the possi-
ble role of nonadipose tissue in metabolic dysregulation in
MOPDII, pericentrin mRNA expression was assessed in
a range of human tissues. Expression was dramatically
higher in skeletal muscle compared with any other tissue,
at over 15 times higher than in the brain, which had the
second highest expression level, and almost 100 times
higher than in white adipose tissue (Fig. 4A). The pre-
ponderance of pericentrin mRNA expression in human
skeletal muscle was not replicated in mouse tissues, where
expression was more uniform, with the highest expression
in the heart, followed by the pancreas, skeletal muscle,
and white adipose tissue (Fig. 4B). Immunostaining of
human skeletal muscle for pericentrin revealed it to have
a perinuclear distribution quite distinct from the punctate
centrosomal localization seen in other cell types (Fig. 4C).
This is consistent with previous studies in murine cells,
suggesting that the microtubule organizing center in dif-
ferentiating myoblasts changes from a punctate to a cir-
cumferential structure, with redistribution of pericentrin
during this process.
DISCUSSION
MOPDII is a rare syndrome of extreme, growth-hormone
resistant intrauterine and postnatal growth retardation,
characteristic facial dysmorphism, and widespread bone
and dental dysplasia (22). Premature death frequently
results from intracranial hemorrhage secondary to moya
moya–like cerebrovascular abnormalities and intracranial
aneurysms (23). Despite severe microcephaly, intelligence
is generally normal or only mildly impaired in the absence
of cerebrovascular events.
We now report that severe insulin resistance, diabetes,
and dyslipidemia are common features of MOPDII asso-
ciated with PCNT mutations. Our observation of infants
with PCNT mutations and normal insulin sensitivity, in-
cluding one patient with a severely insulin-resistant 13-
year-old sibling, allied to the clinical histories of older
patients with severe insulin resistance, suggest that insulin
resistance is not congenital but rather becomes manifest
most commonly between 5 and 10 years of age. In two cases,
insulin resistance was ﬁrst noted during growth-hormone
FIG. 3. Knockdown of Pcnt results in mildly impaired insulin-stimulated
glucose uptake with normal proximal insulin signaling and GLUT4 lo-
calization in adipocytes. A: Insulin-stimulated phosphorylation of in-
sulin receptor (INSR), AKT and extracellular signal–regulated kinase
(ERK) 1/2 after a 5-min treatment of serum-starved mature adipocytes
with 100 nmol/L insulin, assessed by Western blotting. Representative
example of three independent experiments. B: Relative [3H]deoxy-
glucose uptake by Pcnt knockdown (□ and ▨) and control (■) adi-pocytes after serum starvation and treatment with 100 nmol/L insulin
or PBS for 30 min. ***P < 0.005 vs. insulin treatment; aP < 0.005 vs.
shLuc after PBS treatment; bP < 0.005 vs. shLuc after insulin treat-
ment. Values are means 6 SE (n = 9). C: Coimmunostaining of peri-
centrin (green) and endogenous GLUT4 (red) in shLuc (top panel) and
shPcnt (bottom panel) mature adipocytes. Far right, magniﬁed image.
Blue = DAPI. Scale bar: 5 mm. AU, arbitrary units. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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therapy. MOPDII is not a growth hormone–deﬁcient state,
and because growth-hormone therapy is both ineffective in
promoting linear growth and is known to exacerbate in-
sulin resistance, we suggest that growth hormone should
be avoided in MOPDII.
Although no formal assessment of the prevalence of
insulin resistance in MOPDII or PCNT-opathy has been
previously conducted, previous reports, including a large
case series, attest to the occurrence of acanthosis ni-
gricans, ﬂexural hyperpigmentation worsening with growth-
hormone therapy or puberty (hallmarks of acanthosis
nigricans), or skin tags in a signiﬁcant number of patients
with a clinical diagnosis of MOPDII (7,8,22). Furthermore,
as many as one-third of female patients with MOPDII ex-
hibit precocious puberty, and polycystic ovary syndrome
has been conﬁrmed in at least one patient (22). Both pre-
cocious puberty and polycystic ovary syndrome are char-
acteristics of severe insulin resistance, although they also
have other etiologies. Our ﬁnding of highly prevalent se-
vere insulin resistance in those with PCNT defects is
therefore consistent with earlier clinical reports.
This demonstration that severe insulin resistance is
common in MOPDII emphasizes that appropriate and
regular surveillance for metabolic disease, including mea-
surements of fasting glucose, lipid proﬁle, and liver func-
tion, should be part of the routine management of patients
with MOPDII. It also suggests that physiological lessons
may be learned from MOPDII as a human “experiment of
nature,” potentially providing insight into the pathogenic
mechanisms behind the complex phenotype of prevalent
FIG. 4. Pericentrin expression in human and murine tissues. Pcnt mRNA expression in a panel of human (A) and murine (B) tissues determined by
quantitative real-time PCR. A: Data are means 6 SE. Sample sizes are in parentheses. B: Data represent n = 1. C: Immunostaining of pericentrin
(red) in human vastus lateralis sections. Nuclei stained with DAPI. Lower panel shows magniﬁed images. Scale bars: 5 mm (top) and 1 mm
(bottom). AU, arbitrary units; BAT, brown adipose tissue; Cortex, cerebral cortex; Hypoth, hypothalamus; mWAT, mesenteric white adipose tissue;
scWAT, subcutaneous white adipose tissue; SkM, skeletal muscle; SmInt, Small intestine; WAT, white adipose tissue. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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insulin resistance. Indeed, patients with PCNT defects with
severe insulin resistance represent a more faithful model
of the metabolic syndrome than patients with insulin re-
ceptor defects, who exhibit extreme hyperinsulinemia and
ultimately hyperglycemia but are not dyslipidemic and are
protected from hepatic steatosis (15). In contrast, patients
with PCNT defects exhibit not only hyperinsulinemia,
which may be extreme, but also are severely dyslipidemic
and have hepatic steatosis. Furthermore, although recep-
toropathy is associated with elevated adiponectin, sex
hormone–binding globulin (SHBG), and IGF-binding pro-
tein 1 (IGFBP1), all these markers of tissue-speciﬁc insulin
action are suppressed in the context of PCNT loss of
function (8). The metabolic phenotype observed in MOPDII
therefore mimics, in severe forms, that of morbid obesity
or lipodystrophy, each of which may be viewed as exam-
ples of adipose failure. Although a centripetal fat distri-
bution is frequently noted in patients with PCNT defects,
the preservation of adipose tissue on the limbs, total body
fat content, and leptin levels collectively rule out frank
lipodystrophy. This raises the possibility that pericentrin
deﬁciency may lead to a primary defect in adipocyte in-
sulin action without major impairment of adipose tissue
development.
Although complete pericentrin deﬁciency produces se-
vere insulin resistance and diabetes, the lack of metabolic
phenotype in the relatives of patient 1, who are effectively
haploinsufﬁcient for pericentrin, argues that a loss of 50%
of pericentrin function is insufﬁcient to perturb metabo-
lism and suggests that milder, more common variation in
pericentrin expression or function is unlikely to contribute
to prevalent forms of insulin resistance and diabetes.
Published data (11) have implicated pericentrin in nor-
mal function of the mitotic spindle; it is likely also to help
nucleate interphase microtubules. Thus, PCNT mutations
may impair the generation of adequate numbers of adipo-
cytes at puberty or during growth-hormone therapy as
a result of mitotic defects in preadipocytes or mesenchy-
mal stem cells, leading to the production of fewer hyper-
trophic, unhealthy adipocytes with reduced capacity for
energy storage. Here, we have provided evidence in sup-
port of this model by demonstrating that knockdown
of pericentrin results in impaired cell proliferation, adi-
pogenesis, and triglyceride accumulation in 3T3-L1 pre-
adipocytes, similar to the consequences of knockdown of
ALMS1, another large centrosomal protein of unknown
function (24). Defects in ALMS1 cause Alström syndrome,
which also features severe insulin resistance and dyslipi-
demia that are disproportionate to adiposity (25,26).
A stoichiometric association of the regulatory subunit of
phosphatidyl inositol 3-kinase with the centrosome in re-
sponse to insulin action has been reported, suggesting that
the centrosome may play a role in early events in insulin
signal transduction (27). PCNT defects also lead to de-
ranged microtubule architecture, which might be expected
to perturb intracellular localization and trafﬁcking of
GLUT4 vesicles within adipocytes. However, we found no
evidence of a defect in either proximal insulin signaling
or in insulin-stimulated glucose uptake after pericentrin
knockdown in 3T3-L1 preadipocytes.
It remains to be determined whether the mild differen-
tiation defect caused by loss of PCNT expression in pre-
adipocytes is sufﬁcient to account for severe insulin
resistance in vivo. Indeed, the severity of insulin resistance
in MOPDII, which is at least as great as that in congenital
generalized lipodystrophy, suggests that other factors may
be at play. Our ﬁnding of highly abundant pericentrin in
human skeletal muscle raises the possibility that it may be
involved in muscle insulin action. Despite the extremely
high expression of pericentrin in skeletal muscle, however,
patients with PCNT defects show no clinical evidence
of myopathy. Moreover, no cellular models reliably re-
capitulate insulin-stimulated, GLUT4-mediated glucose up-
take, precluding in vitro study in this case; future in vivo
studies are therefore required.
One recent report (28) using cultured cells and mice
transplanted with pancreatic islets with or without peri-
centrin knockdown suggested that pericentrin deﬁciency
may lead to insulin hypersecretion in the fasting state, with
reduced ability to clear a glucose load. However, our hu-
man observations show unequivocal and severe insulin
resistance, with neither clinical nor biochemical evidence
of antecedent hypoglycemia. Furthermore, although high
levels of insulin may lead to insulin receptor down-
regulation, there are no reported precedents for primary
insulin hypersecretion as a cause of severe systemic in-
sulin resistance. Collectively, these observations argue
against dysregulation of insulin secretion as the dominant
defect underlying insulin-resistant diabetes in MOPDII.
In summary, we establish that MOPDII, a syndrome of
primordial dwarﬁsm attributed to loss of function of peri-
centrin, also encompasses severe insulin resistance, di-
abetes, and dyslipidemia. This appears to manifest most
commonly between age 5 and 15 years and may be un-
masked by growth-hormone therapy. Equivalent loss of
pericentrin in vitro leads to impaired adipocyte differenti-
ation with commensurately reduced insulin-stimulated glu-
cose uptake, possibly secondary to impaired preadipocyte
proliferation. Additional elucidation of the mechanisms
whereby defects in pericentrin lead to insulin resistance in
vivo may not only enhance understanding of this rare
condition but also may offer insights into the pathogenesis
of common insulin resistance.
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